Trivalent Influenza Vaccine in Preventing Flu in Patients With Central Nervous System Tumors
NCT01474174
Completed
This pilot clinical trial studies trivalent influenza vaccine in preventing flu in patients with central nervous system (CNS) tumors. Flu vaccine may help the body build an effective immune response and help prevent flu in patients who are receiving chemotherapy for CNS tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2018
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Central Nervous System Neoplasm
Register for Updates
High-Dose Trivalent Influenza Vaccine in Inducing Immune Response Patients With Central Nervous System Tumors
NCT01941758
Completed
This pilot clinical trial studies high-dose trivalent influenza vaccine in inducing immune response patients with central nervous system tumors. Studying samples of blood in the laboratory from patients receiving trivalent influenza vaccine may help doctors learn more about the effects of trivalent influenza vaccine on cells. It may also help doctors understand how well patients respond to treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2018
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland +1 locations
Conditions: Central Nervous System Neoplasm
Register for Updates
Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age
NCT01659086
Completed
The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity of different formulations of a two-dose primary series and booster vaccination of monovalent Influenza H9N2 vaccine manufactured in Quebec, Canada with and without adjuvant, in adults 18 to 64 years of age.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
06/14/2018
Locations: GSK Investigational Site, Miami, Florida +3 locations
Conditions: Influenza
Register for Updates
Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old
NCT02035696
Completed
To evaluate the safety and immunogenicity of four influenza vaccines in children 6 months to \< 48 months of age
Gender:
ALL
Ages:
Between 6 months and 48 months
Trial Updated:
06/11/2018
Locations: Site 116, Phoenix, Arizona +26 locations
Conditions: Influenza
Register for Updates
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years
NCT00719043
Completed
The purpose of this study is to determine whether GSK's avian flu vaccine GSK 1557484A is immunogenic and safe when given to adults aged \>=18 years. This Protocol Posting has been updated following Amendments 1-3 of the Protocol, Dec 2009. The impacted sections are study design and outcome measures.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/08/2018
Locations: GSK Investigational Site, Denver, Colorado +12 locations
Conditions: Influenza
Register for Updates
Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women
NCT02360475
Completed
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of different formulations of a single intramuscular dose of GSK Biologicals' investigational RSV vaccine, in healthy, non-pregnant women aged 18 to 45 years.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
05/31/2018
Locations: GSK Investigational Site, Mesa, Arizona +11 locations
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children
NCT02207413
Completed
The purpose of this trial is to demonstrate the acceptable safety profile and the immunological non-inferiority of the FLU D-QIV vaccine manufactured with this investigational process (FLU D-QIV Investigational Process \[IP\]) compared to FLU D-QIV manufactured with the current licensed process (FLU D-QIV Licensed Process \[LP\]).
Gender:
ALL
Ages:
Between 6 months and 49 years
Trial Updated:
05/31/2018
Locations: GSK Investigational Site, Wichita, Kansas +52 locations
Conditions: Influenza
Register for Updates
Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine
NCT02868073
Completed
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Norovirus Vaccine (VXA-G1.1-NN) Expressing GI.1 VP1 and dsRNA Adjuvant Administered Orally to Healthy Volunteers
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
05/29/2018
Locations: Celerion, Inc., Lincoln, Nebraska
Conditions: Norovirus Gastroenteritis
Register for Updates
Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant
NCT01174082
Terminated
The goal of this clinical research study is to learn if vaccinating a donor with your purified myeloma protein and then injecting it back into you will help your immune system control the multiple myeloma.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/29/2018
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Myeloma
Register for Updates
Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy Adults
NCT03121339
Completed
This is a phase 1 open-label pharmacodynamics study in healthy adults. The purpose of the study is to determine if the tablet formulation size of VXA-A1.1, an adjuvanted adenoviral based influenza vaccine, has an impact on delivery location. The secondary objective is to evaluate delivery with fasting versus fed status.
Gender:
MALE
Ages:
Between 18 years and 49 years
Trial Updated:
05/29/2018
Locations: Scintipharma, Inc., Lexington, Kentucky
Conditions: Seasonal Influenza Preventative Vaccine Pharmacodynamics
Register for Updates
Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers
NCT03125473
Completed
A Phase 1b, randomized, double-blind, dose-ranging trial to determine the safety of different dosing regimens an adenoviral-vector based norovirus vaccine (VXA-G1.1-NN) expressing GI.1 VP1 and dsRNA adjuvant administered orally to healthy volunteers
Gender:
ALL
Ages:
Between 19 years and 49 years
Trial Updated:
05/29/2018
Locations: Celerion, Inc., Lincoln, Nebraska
Conditions: Norovirus Gastroenteritis
Register for Updates
DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC
NCT00085436
Completed
RATIONALE: Vaccines made from a patient's dendritic cells and tumor cells may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's lymphocytes to kill kidney cancer cells. Interferon alfa may interfere with the growth of cancer cells. Combining vaccine therapy with interleukin-2 and interferon alfa may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving vaccine therapy together with interleukin-2 and interferon alfa works... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2018
Locations: Norris Cotton Cancer Center at Dartmouth - Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Kidney Cancer
Register for Updates